Eagle Health Investments’s Vir Biotechnology VIR Stock Holding History

Eagle Health Investments’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-240,500	Closed	-$1.45M	–	37
2025 Q4	$1.45M	Hold	240,500	–	–	0.32%	30
2025 Q3	$1.37M	Hold	240,500	–	–	0.36%	23
2025 Q2	$1.21M	Hold	240,500	–	–	0.3%	21
2025 Q1	$1.56M	Buy	+240,500	New	+$2.14M	0.4%	19

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GSK plc London $602M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Eagle Health Investments's VIR Position: Q1 2026 in Review

Eagle Health Investments sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 240,500 shares — an estimated $1.45M sold.

Eagle Health Investments first reported a position in VIR in Q1 2025 and held it in 4 quarters. The position peaked at $1.56M in Q1 2025. 252 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

Eagle Health Investments reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
Eagle Health Investments sold 240,500 Vir Biotechnology shares in Q1 2026, an estimated $1.45M.
Eagle Health Investments first reported a position in Vir Biotechnology in Q1 2025 and held it in 4 quarters.
Eagle Health Investments's Vir Biotechnology position peaked at $1.56M in Q1 2025.
252 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Eagle Health Investments's 13F filing for Q1 2026, filed 15 May 2026.